<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03308955</url>
  </required_header>
  <id_info>
    <org_study_id>2011-KAEK-25 2017-13/69</org_study_id>
    <nct_id>NCT03308955</nct_id>
  </id_info>
  <brief_title>Analgesic Effect of Quadratus Lumborum Block Application After Laparoscopic Cholecystectomy Surgery</brief_title>
  <official_title>Analgesic Effect of Ultrasound Guided Quadratus Lumborum Block Application After Laparoscopic Cholecystectomy Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bursa Yüksek İhtisas Education and Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bursa Yüksek İhtisas Education and Research Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Laparoscopy is frequently used today for intraabdominal operations. Laparoscopic procedure
      has become the treatment of choice for many patients with symptomatic cholelithiasis.
      Patients undergoing laparoscopic cholecystectomy suffer from acute postoperative pain,
      despite a multimodal analgesic regime.

      This is a randomised controlled trial efficay of the Quadratus Lumborum (QL) Block in terms
      of analgesic efficacy in patients who undergo laparoscopic cholecystectomy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 22, 2017</start_date>
  <completion_date type="Actual">December 2, 2017</completion_date>
  <primary_completion_date type="Actual">August 22, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>prospective,randomized,single blind</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Single (Outcomes Assessor)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Analog Pain Scale</measure>
    <time_frame>Postoperative 24 hours</time_frame>
    <description>Visual Analog Pain Scale was used for pain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>tramadol consumption</measure>
    <time_frame>Postoperative 24 hours</time_frame>
    <description>tramadol consumption</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>side effect profile scores)</measure>
    <time_frame>Postoperative 24 hour</time_frame>
    <description>side effect profile (including nausea and vomiting, hypotension,requirement and the Ramsay Sedation Scale (RSS) scores)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>additional analgesic use</measure>
    <time_frame>Postoperative 24 hour</time_frame>
    <description>additional analgesic use</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Cholecystectomy</condition>
  <condition>Postoperative Pain</condition>
  <condition>Nerve Block</condition>
  <arm_group>
    <arm_group_label>Grup B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ultrasound guided Quadratus Lumborum block type II with 0.3 ml/kg % 0.25 bupivakain+ 400 mg tramadol, IV 4 mg/ mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Grup S</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Ultrasound guided Quadratus Lumborum block type II with 0.3 ml/kg saline % 0,9+ 400 mg tramadol, IV 4 mg/ mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tramadol</intervention_name>
    <description>400 mg tramadol, IV 4 mg/ mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.</description>
    <arm_group_label>Grup B</arm_group_label>
    <arm_group_label>Grup S</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ultrasound guided Quadratus Lumborum block</intervention_name>
    <description>Ultrasound guided Quadratus Lumborum block type II with 0.3 ml/kg % 0.25 bupivakain+400 mg tramadol, IV 4 mg/ mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.</description>
    <arm_group_label>Grup B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ultrasound guided placebo Quadratus Lumborum block</intervention_name>
    <description>Ultrasound guided placebo Quadratus Lumborum block type II with 0.3 ml/kg saline % 0,9+400 mg tramadol, IV 4 mg/ mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.</description>
    <arm_group_label>Grup S</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -Patients who were in the American Society of Anesthesiologists (ASA) I-III class and
        underwent Laparoscopic Cholecystectomy

        Exclusion Criteria:

          -  Previous history of opioid use preoperatively,

          -  Allergy to local anesthetics,

          -  The presence of any systemic infection,

          -  Uncontrolled arterial hypertension,

          -  Uncontrolled diabetes mellitus.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Korgün Ökmen, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Health Sciences, Bursa Yuksek Ihtisas Training and Research Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Health Sciences,,Bursa Yuksek Ihtisas Training and Research Hospital,</name>
      <address>
        <city>Bursa</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 4, 2017</study_first_submitted>
  <study_first_submitted_qc>October 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 13, 2017</study_first_posted>
  <last_update_submitted>December 27, 2017</last_update_submitted>
  <last_update_submitted_qc>December 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bursa Yüksek İhtisas Education and Research Hospital</investigator_affiliation>
    <investigator_full_name>Korgün Ökmen</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Analgesics</mesh_term>
    <mesh_term>Tramadol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

